Pfizer Gets Setback In Lipitor Patent Battle

Law360, New York (August 30, 2006, 12:00 AM EDT) -- Lending a boost to Ranbaxy Laboratories’ global crusade, a Norwegian court has denied Pfizer Inc.’s claim that the Indian drug maker has infringed two patents related to blockbuster cholesterol drug Lipitor.

On Wednesday, the Oslo City Court sided with Ranbaxy, ruling that the company was not guilty of infringing two of Pfizer’s four Norwegian patents covering the cholesterol treatment.

"This is a most important decision for Ranbaxy, as it significantly validates our position regarding the atorvastatin patents," said Jay Deshmukh, senior vice president, global intellectual property...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.